Immuneering Corp Stock Performance
| IMRX Stock | USD 1.94 0.03 1.57% |
On a scale of 0 to 100, Immuneering Corp holds a performance score of 3. The company retains a Market Volatility (i.e., Beta) of 1.28, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Immuneering Corp will likely underperform. Please check Immuneering Corp's maximum drawdown, as well as the relationship between the skewness and day typical price , to make a quick decision on whether Immuneering Corp's current trending patterns will revert.
Risk-Adjusted Performance
3 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Immuneering Corp are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Immuneering Corp showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 72.6 M |
Immuneering |
Immuneering Corp Relative Risk vs. Return Landscape
If you would invest 186.00 in Immuneering Corp on November 3, 2024 and sell it today you would earn a total of 8.00 from holding Immuneering Corp or generate 4.3% return on investment over 90 days. Immuneering Corp is currently generating 0.2323% in daily expected returns and assumes 5.7405% risk (volatility on return distribution) over the 90 days horizon. In different words, 51% of stocks are less volatile than Immuneering, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Immuneering Corp Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Immuneering Corp's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Immuneering Corp, and traders can use it to determine the average amount a Immuneering Corp's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0405
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | IMRX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.74 actual daily | 51 51% of assets are less volatile |
Expected Return
| 0.23 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 3 97% of assets perform better |
Based on monthly moving average Immuneering Corp is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Immuneering Corp by adding it to a well-diversified portfolio.
Immuneering Corp Fundamentals Growth
Immuneering Stock prices reflect investors' perceptions of the future prospects and financial health of Immuneering Corp, and Immuneering Corp fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Immuneering Stock performance.
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.37 | ||||
| Current Valuation | 13.82 M | ||||
| Shares Outstanding | 31.05 M | ||||
| Price To Book | 1.04 X | ||||
| Price To Sales | 563.62 X | ||||
| Revenue | 455 | ||||
| EBITDA | (58.06 M) | ||||
| Cash And Equivalents | 128.1 M | ||||
| Cash Per Share | 4.85 X | ||||
| Total Debt | 4.46 M | ||||
| Debt To Equity | 0.04 % | ||||
| Book Value Per Share | 3.09 X | ||||
| Cash Flow From Operations | (48.97 M) | ||||
| Earnings Per Share | (1.97) X | ||||
| Total Asset | 102.58 M | ||||
| Retained Earnings | (163.26 M) | ||||
About Immuneering Corp Performance
Evaluating Immuneering Corp's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Immuneering Corp has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Immuneering Corp has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited. Immuneering Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 74 people.Things to note about Immuneering Corp performance evaluation
Checking the ongoing alerts about Immuneering Corp for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Immuneering Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Immuneering Corp had very high historical volatility over the last 90 days | |
| Immuneering Corp may become a speculative penny stock | |
| The company reported the previous year's revenue of 455. Net Loss for the year was (53.47 M) with profit before overhead, payroll, taxes, and interest of 158.83 K. | |
| Immuneering Corp currently holds about 128.1 M in cash with (48.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.85, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 29.0% of the company shares are held by company insiders |
- Analyzing Immuneering Corp's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Immuneering Corp's stock is overvalued or undervalued compared to its peers.
- Examining Immuneering Corp's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Immuneering Corp's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Immuneering Corp's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Immuneering Corp's stock. These opinions can provide insight into Immuneering Corp's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Immuneering Stock Analysis
When running Immuneering Corp's price analysis, check to measure Immuneering Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immuneering Corp is operating at the current time. Most of Immuneering Corp's value examination focuses on studying past and present price action to predict the probability of Immuneering Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immuneering Corp's price. Additionally, you may evaluate how the addition of Immuneering Corp to your portfolios can decrease your overall portfolio volatility.